Status:
COMPLETED
Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma
Lead Sponsor:
GlaxoSmithKline
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare once and twice daily GW685698 in asthma
Eligibility Criteria
Inclusion
- Key
- Clinical diagnosis of Asthma
- Reversibility ≥ 12% and ≥200mls reversibility of FEV1 within approximately 30-minutes following 2 to 4 puffs of albuterol
- FEV1 between 40-85% predicted
- Currently on short acting beta2 agonist therapy
- Key
Exclusion
- History of life threatening asthma
- Respiratory Infection or oropharyngeal candidiasis
- Asthma exacerbation
- Uncontrolled disease or clinical abnormality
- Allergies
- Taking another Investigational medications or other prohibited medications
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT00766090
Start Date
October 1 2008
End Date
March 1 2009
Last Update
December 8 2016
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Long Beach, California, United States, 90806
2
GSK Investigational Site
Long Beach, California, United States, 90808
3
GSK Investigational Site
Torrance, California, United States, 90505
4
GSK Investigational Site
Cocoa, Florida, United States, 32927